Key Drivers
- Cash Cushion
- Persistent Losses
- Weak Cash Flow
AIAI Summary
PLSE is now an execution-driven, high-momentum catalyst story rather than just a cash-burning biotech, with ahead-of-schedule NANOPULSE-AF enrollment and a strong balance sheet extending runway, but the stock's upside now depends on converting trial progress into regulatory credibility without further dilution or timing slippage.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Cash Cushion
- •Persistent Losses
- •Weak Cash Flow
PLSE has a strong cash-backed balance sheet and low leverage, but persistent losses, negative free cash flow, and an extremely stretched valuation make the stock hard to justify at current revenue levels.
Price Behavior
Key Price Behavior Insights:
- •Higher-high trend
- •Near resistance
- •Pullback risk
PLSE has surged over the last month in a strong higher-high/higher-low uptrend to $44.54, but it is now extended near resistance at $45 with a short-term pullback toward $41.50–$38.20 the main risk.
Rapid rise from $28.68 to $44.54 shows extension and raises retracement risk
Sentiment & News
Key News Insights:
- •Enrollment midpoint
- •Cash cushion
- •Wider Q2 loss
Pulse Biosciences is making steady clinical progress with its NANOPULSE-AF pivotal study crossing the enrollment midpoint and maintaining a strong cash position, but its latest quarter showed wider-than-expected losses and minimal revenue.
The update is mildly constructive for PLSE because advancing trial execution and ample liquidity support the long-term story, even as near-term profitability remains weak
Similar Companies in Healthcare
Other companies in the same sector with AI ratings